Race Oncology Ltd (ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks with Proactive soon after launching a new corporate strategy focused on maximising bisantrene’s anti-cancer and cardio-protective potential. The company’s lead clinical focus will be on investigating anti-cancer, plus cardio-protective and FTO (fat mass and obesity-associated protein) properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer.
Race Oncology at the heart of cancer care
